Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
about
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Is TIMP-1 immunoreactivity alo ...... ast cancer chemotherapy trial?
@en
type
label
Is TIMP-1 immunoreactivity alo ...... ast cancer chemotherapy trial?
@en
prefLabel
Is TIMP-1 immunoreactivity alo ...... ast cancer chemotherapy trial?
@en
P2093
P2860
P356
P1476
Is TIMP-1 immunoreactivity alo ...... ast cancer chemotherapy trial?
@en
P2093
Alison F Munro
Annette Bartels
Christopher J Twelves
David A Cameron
Eva Balslev
John M S Bartlett
Nils Brünner
P2860
P2888
P356
10.1186/BCR3411
P577
2013-04-09T00:00:00Z
P5875
P6179
1014252494